Charles Cen
Head, Business Development Mabwell (Shanghai) Bioscience Co., Ltd.
Seminars
Monday 3rd November 2025
Highlighting Strategy for Selecting the Right ADC Combination Partner & Exploring Results From Preclinical & Clinical Studies
11:30 am
- Exploring clinical-stage trial design and results for Nectin-4 ADC-PD1 combinations
- Laying out rationale for CDH17 and B7H3 ADC combination partner selection
- Assessing emerging preclinical results from CDH17 and B7H3 ADC combination investigation compared to monotherapies
